Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortPD-1 immunotherapy, often combined with ipilimumab.Immunotherapy for many cancers — the world's top-selling medicine.
Body systemCancerCancer
Drug classImmune checkpoint inhibitorsImmune checkpoint inhibitors
SupplyPrescription onlyPrescription onlyWHO essential medicine
Main usesMelanoma, Lung cancer, Kidney cancer, Oesophageal and stomach cancer, Hodgkin lymphomaMelanoma, Non-small cell lung cancer, Kidney, bladder, head and neck cancers, Triple-negative breast cancer, Cervical and endometrial cancer
How it worksReleases a brake on immune cells so they attack cancer.Takes the brakes off your immune cells so they can find and kill cancer.
Starts working——
Half-lifeAbout 25 daysAbout 22 days
Typical adult dose240 mg every 2 weeks or 480 mg every 4 weeks IV.200 mg every 3 weeks or 400 mg every 6 weeks IV.
FormsIV infusion, Subcutaneous injectionIV infusion, Subcutaneous injection
Common side effectsTiredness, Rash, Diarrhoea, Thyroid problemsTiredness, Rash and itch, Diarrhoea, Underactive thyroid
Serious side effectsPneumonitis, Colitis, Hepatitis, Endocrine failurePneumonitis, Colitis, Hepatitis, Type 1 diabetes, Myocarditis, Adrenal or pituitary failure
Don't take if——
Alcohol——
PregnancyUsually avoidedContraception needed.Usually avoidedContraception needed.
Breastfeeding——
In use since20142014
Brand namesUnited States: Opdivo, Opdivo QvantigUnited Kingdom: OpdivoIndia: Opdyta, OpdivoUnited States: Keytruda, Keytruda QlexUnited Kingdom: KeytrudaIndia: Keytruda
Legal status——
ATC codeL01FF01L01FF02

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker